Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

5.560 -0.370 (-6.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,939,209
Open 6.000
Bid (Size) 5.750 (10,900)
Ask (Size) 5.800 (12,100)
Prev. Close 5.930
Today's Range 5.430 - 6.270
52wk Range 5.430 - 20.75
Shares Outstanding 45,711,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tesla Chair Declares Start Of 'Whole New Book' As Musk's 423 Million Share Award Is Locked In — All Hope Pinned On Robotaxi, Optimus
Via Stocktwits
Top Stocks With Earnings This Week: Plug, Oklo, Circle And More
Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle. 
Via Benzinga

Performance

YTD
-62.8%
-62.8%
1 Month
-17.3%
-17.3%
3 Month
-28.9%
-28.9%
6 Month
-21.8%
-21.8%
1 Year
-71.5%
-71.5%

More News

Read More
Earnings Scheduled For November 10, 2025
Via Benzinga
Preview: Capricor Therapeutics's Earnings
Via Benzinga
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback
Via Stocktwits
Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder
Via Stocktwits
CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why Capricor Therapeutics Stock Is Surging Today
Via Benzinga
Gapping stocks in Thursday's session
Via Chartmill
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR
From Faruqi & Faruqi, LLP
Via Business Wire
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
CAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Capricor Therapeutics, Inc. of the September 15th Deadline for the Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Lawsuit - CAPR
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Lawsuit - CAPR
Via TheNewswire.com
Topics Fraud Lawsuit
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
CAPR DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPR
From The Rosen Law Firm PA
Via GlobeNewswire
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025 - CAPR
Via NewMediaWire
Topics Fraud Lawsuit
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025 - CAPR
Via TheNewswire.com
Topics Fraud Lawsuit
CAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Capricor Therapeutics, Inc. of the September 15th Deadline for the Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) - September 15, 2025 Deadline to Join - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) - September 15, 2025 Deadline to Join - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit

Frequently Asked Questions

Is Capricor Therapeutics, Inc. - Common Stock publicly traded?
Yes, Capricor Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Capricor Therapeutics, Inc. - Common Stock trade on?
Capricor Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Capricor Therapeutics, Inc. - Common Stock?
The ticker symbol for Capricor Therapeutics, Inc. - Common Stock is CAPR on the Nasdaq Stock Market
What is the current price of Capricor Therapeutics, Inc. - Common Stock?
The current price of Capricor Therapeutics, Inc. - Common Stock is 5.560
When was Capricor Therapeutics, Inc. - Common Stock last traded?
The last trade of Capricor Therapeutics, Inc. - Common Stock was at 11/10/25 04:00 PM ET
What is the market capitalization of Capricor Therapeutics, Inc. - Common Stock?
The market capitalization of Capricor Therapeutics, Inc. - Common Stock is 254.16M
How many shares of Capricor Therapeutics, Inc. - Common Stock are outstanding?
Capricor Therapeutics, Inc. - Common Stock has 254M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.